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Diabetes mellitus increases the risk and accelerates the 
clinical course of atherosclerosis, and is responsible for 
majority of the deaths and disabilities in type 2 diabetic 
population.[1] Optimal strategies to prevent the onset or 
progression of atherosclerosis will improve the clinical 
outcome of this high-risk population. In the current 
study, the research team showed that two antidiabetic 
agents, namely Glimepiride and Repaglinide, prevent the 
progression of atherosclerosis in high fat diet fed rabbits, by 
exerting their anti-inflammatory and anti-oxidative effects.
Clue to these new findings came from prior observations 
about the effects of Glimepiride in atherosclerosis. 
Sulfonylureas derivatives stimulated insulin secretion o 
from the beta cells of the pancreas, and have been widely 
used in the treatment of diabetes. Glimepiride is a third-
generation Sulfonylurea agent with less insulin-secreting 
effects compared with conventional Sulfonylureas agents. 
In vitro, Glimepiride leads to improved lipid metabolism, 
enhances endothelial function due to the biosynthesis of 
nitric monoxide, and has displayed anti-oxidative effects.[2,3] 
In vivo in type 2 diabetic patients, Glimepiride demonstrated 
anti-atherosclerotic abilities.[4] Consistently, in cholesterol-
fed rabbits, Glimepiride treatment produced significant 
reduction in atherosclerosis lesions with no significant 
changes observed in the levels of plasma lipids.[5] However, 
the precise mechanisms of the athero-protective actions 
of Glimepiride remain unknown.
In the current study, the research team assessed the effect 
of glimepiride on atherosclerosis using rabbits fed with 
1% cholesterol enriched diet.[6] Consistent with previous 
studies, they found that Glimepiride treatment significantly 
reduced aortic intimal thickness without modulating lipid 
parameters, compared with the induced untreated group. 
They demonstrated that in the Glimepiride-treated group 
there was a decrease in the levels of pro-inflammatory 
biomarkers and cytokines, including high sensitive   
C- reactive protein (hsCRP), Interleukin – 6 (IL-6) 
and Tumor Necrosis Factor alpha (TNF-α). They 
further showed that Glimepiride treatment resulted in 
reduced levels of aortic oxidation biomarkers including 
Malondialdehyde (MDA) and reduced glutathione (GSH).
In addition, the research team also investigated the 
effects of another insulin secretagoguo, Repaglinide in 
the development of atherosclerosis. Repaglinide belongs 
to the Meglitinide class of blood glucose-lowering 
drugs. Meglitinide derivatives also stimulate the release 
of insulin from pancreas. They are able to do so by 
shutting down Adenosine triphosphate (ATP)-dependent 
potassium channels in the membrane of beta cells. This 
action depolarizes cells and stimulates calcium influx by 
opening up calcium channels, resulting in an increase in 
insulin secretion. In the current study, the research team 
found that, similar to Glimepiride, Repaglinide decreased 
the aortic intimal thickness, reduced the levels of pro-
inflammatory biomarkers and cytokines, and displayed anti-
oxidative activities in cholesterol-fed rabbits. It achieves 
this without affecting the levels of plasma lipid. The results 
suggest that Repaglinide has anti-atherosclerotic effects by 
suppressing inflammation and oxidative stress.
These observations led to a set of intriguing questions. How 
do Glimepriride and Repaglinide suppress inflammation 
and oxidative stress without affecting lipid parameters? 
Glimepriride has been demonstrated to have actions 
other than stimulating insulin secretion, including 
phosphorylation of insulin receptor substrate-1, inhibition 
of cellular cyclooxygenase pathways and up-regulating 
antioxidant enzyme levels. It remains to be elucidated 
whether the anti-inflammatory and anti-oxidative properties 
of Glimepriride can be attributed to some of these activities. 
Repaglinide is known for its anti-oxidant effects. Whether 
its anti-oxidant activity accounts for its anti-inflammatory 
action also remains to be determined. Finally, it is possible 
that these two oral antidiabetic agents may have activities 
beyond their anti-inflammatory and anti-oxidant effects that 
contribute to their athero-protective effects.
In conclusion, the current study provides useful insights 
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into the cardiovascular effects of two commonly-
used oral antidiabetic drugs. It also identified two 
potential mechanisms by which these two insulin 
secretagogue achieve anti-atherosclerotic effects. These 
significant findings will have important implications for 
identifying the optimal strategy for treating patients with 
atherosclerosis and type 2 diabetes.
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